This in vivo study and clinical evidence confirmed the hypothesis of atorvastatin-induced senescence and the crucial role of the IL-6/STAT3/TERT signaling pathway in HCC progression in vivo. This evidence concerns the gene IL6 and hepatocellular carcinoma.